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Introduction
Breast cancer is the most commonly occurring cancer in women. 
It comprises 22% of all cancers1 and is second only to lung cancer 
as a cause of cancer related death in women.2 Over the past few 
decades, there has been no significant decrease in the incidence 
of this disease. Current therapies delay tumor progression sig-
nificantly, but recurrence is almost inevitable, resulting in high 
mortality rates in advanced stages.
Tamoxifen, which functions as a cell type-specific anties-
trogen, has dominated endocrine treatment of breast cancer for 
over 30 years. It is a standard therapeutical treatment in patients 
with estrogen receptor (ERα) positive breast carcinoma with 
demonstrated efficacy in metastatic breast cancer, adjuvant ther-
apy, preoperative treatment and chemoprevention.3 However, 
less than 50% of ERα-positive breast cancers do not respond 
to tamoxifen treatment (intrinsic or de novo resistance) whereas 
Tamoxifen is a standard therapeutical treatment in patients with estrogen receptor positive breast carcinoma. however, 
less than 50% of estrogen receptor positive breast cancers do not respond to tamoxifen treatment whereas 40% of tumors 
that initially respond to treatment develop resistance over time. The underlying mechanisms for tamoxifen resistance 
are probably multifactorial but remain largely unknown. The primary aim of this study was to investigate the impact 
of pTeN tumor suppressor gene on acquiring resistance to tamoxifen by analyzing loss of heterozygosity (LOh) and 
immunohystochemical expression of pTeN in 49 primary breast carcinomas of patients treated with tamoxifen as the only 
adjuvant therapy. The effect of pTeN inactivation on breast cancer progression and disease outcome was also analyzed. 
Reduced or completely lost pTeN expression was observed in 55.1% of samples, while 63.3% of samples displayed LOh 
of pTeN gene. Inactivation of pTeN immunoexpression significantly correlated with the pTeN loss of heterozygosity, 
suggesting LOh as the most important genetic mechanism for the reduction or complete loss of pTeN expression in 
primary breast carcinoma. Most importantly, LOh of pTeN and consequential reduction of its immunoexpression showed 
significant correlation with the recurrence of the disease. Besides, our study revealed that LOh of pTeN tumor suppressor 
was significantly associated with shorter disease free survival, breast cancer specific survival and overall survival. In 
summary, our results imply that LOh of pTeN could be used as a good prognostic characteristic for the outcome of breast 
cancer patients treated with tamoxifen.
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40% of tumors that initially respond to treatment develop 
resistance over time (acquired resistance), despite continued 
expression of ERα.4 The underlying mechanisms for tamoxi-
fen resistance are probably multifactorial but remain largely 
unknown. However, there is a compelling evidence which sug-
gests that increased growth factor signaling, in particular the 
epidermal growth factor receptor (EGFR), human epidermal 
growth factor receptor type 2 (HER2) and insulin-like growth 
factor-1 receptor (IGF-1R) signaling pathways, contribute to 
this resistance.5,6 Moreover, the activity of kinases that functions 
downstream of these receptors, such as AKT, are often elevated 
in non-responsive tumors that exhibit either de novo or acquired 
resistance.7 AKT, also known as protein kinase B (PKB), plays 
an important role in cell proliferation, survival and endocrine 
resistance. Several studies have now demonstrated that PKB/
Akt can protect breast cancer cells from tamoxifen-induced 
apoptosis by modulating ERα activity.8,9 These data suggest a 
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Table 1. Clinical and histopathological characteristics of patients
Patient Age pTa Cancer typeb Tumor gradus pNc DFSd BCSS statuse OSf OS statusg
1 60 2 ILC 2 1 145 0 145 0
2 60 2 ILC 2 1 141 0 141 0
3 68 1 ILC 2 1 76 0 76 0
4 55 2 ILC 3 1 175 0 175 0
5 66 3 IDC 1 1 12 1 24 1
6 70 2 IDC 2 1 95 0 95 1
7 69 2 ILC 2 0 11 0 11 1
8 59 2 ILC 2 1 46 1 63 1
9 57 1 IDC 2 1 96 1 139 1
10 63 1 IDC 2 1 82 0 82 0
11 47 2 IDC 3 0 41 1 110 1
12 64 2 IDC 3 1 108 1 129 1
13 61 2 ILC 2 1 24 1 34 1
14 61 1 ILC 2 1 144 0 144 0
15 43 1 ILC 2 1 139 0 139 0
16 55 2 ILC 2 1 142 0 142 0
17 61 3 IDC 2 1 183 1 183 1
18 48 1 IDC 3 1 28 0 228 0
19 62 2 IDC 2 1 20 1 26 1
20 60 2 ILC 2 1 21 1 23 1
21 63 2 ILC 2 1 15 1 47 1
22 54 2 IDC 2 1 210 0 210 0
23 60 1 ILC 2 1 129 0 213 0
24 76 2 ILC 2 1 76 1 145 1
25 57 1 IDC 2 1 41 1 89 1
26 70 1 IDC 2 1 46 1 47 1
27 66 1 IDC 2 1 58 0 58 1
28 64 2 IDC 2 1 85 1 97 1
29 54 2 IDC 1 1 202 0 202 0
30 66 1 IDC 2 1 153 1 153 1
31 62 2 IDC 2 1 92 1 156 1
32 69 1 IDC 2 1 70 0 70 0
33 54 1 IDC 2 1 46 1 73 1
34 62 1 ILC 2 1 49 1 49 1
35 49 1 IDC 1 1 11 0 11 1
36 62 1 ILC 2 1 85 1 85 1
37 59 1 ILC 2 1 60 0 60 0
38 66 1 IDC 2 1 106 1 155 1
39 58 1 ILC 2 1 220 0 220 0
40 58 2 ILC 2 1 69 0 69 0
41 60 2 IDC 3 1 34 0 70 0
42 68 1 IDC 2 1 123 0 123 0
43 57 1 ILC 2 1 146 0 146 0
44 55 3 IDC 2 1 20 1 52 1
aTumor size: T1 ≤ 20 mm; T2 > 20–50 mm; T3 > 50 mm. bType of breast carcinoma: ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma. 
cLymph node status: 0, without metastases; 1, lymph node metastases present (1–3 lymph nodes). dDisease free survival in months. eBreast cancer 
specific survival status—death caused by breast cancer: 0, no; 1, yes. fOverall survivals in months until the completion of study. gOverall survival status: 
0, alive at the time of the completion of study; 1, died.
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11–220 mo. At the completion of the study, 26 (53.1%) patients 
had died and 23 (46.9%) were alive. Twenty-eight patients had 
invasive ductal breast carcinomas while 21 had invasive lobular 
carcinoma. Out of the total number of 49 patients, lymph node 
metastasis was present in 46 (93.9%), whereas only 3 (6.1%) 
were node negative. Disease recurrence occurred in 22 (44.9%) 
of 49 patients.
Immunophenotype of breast cancer patients. For the purpose 
of testing the patients’ suitability for tamoxifen therapy, immu-
nohistochemical analyses were used to evaluate the expression of 
steroid receptors that is estrogen receptor (ER) and progesterone 
receptor (PR). Estrogen receptor positive status was determined 
in all 49 patients (100%) while 39 (79.6%) patients were proges-
terone receptor positive. In addition, the expression of human 
epidermal growth factor receptor 2 (HER2) was analyzed and 
only 6 (12.2%) patients showed positive status. The results are 
summarized in Table 2.
Disease relapse developed in 22 of 49 patients and did 
not display any correlation with progesterone negative status 
significant role of the PKB/Akt signaling pathway in hormone-
refractory breast cancer.
PKB/AKT is activated by PI3K leading to substrate phosphor-
ylation and cell survival and is counter-balanced by the tumor 
suppressor PTEN (phosphatase and tensin homolog deleted 
on chromosome 10). PTEN has dual phosphatase activity and 
dephosphorilates both lipid and protein substrates. The main 
lipid target of PTEN tumor suppressor is phosphatidylinositol-
(3,4,5)-triphosphate (PIP3) acting as key negative regulator of 
PI3K/Akt signaling pathway thus regulating cell cycle progression 
and survival, cell growth, angiogenesis and genome stability.10 It 
has recently been shown that, in addition to these very important 
tumor suppressing functions, PTEN could play an important 
role in acquiring resistance to tamoxifen.11,12 Specifically, Shoman 
et al.12 showed that decreased PTEN expression significantly cor-
related with the resistance to tamoxifen in ERα-positive breast 
carcinoma patients.
Multiple mechanisms of somatic PTEN inactivation occur 
depending on the type of neoplasia involved. Reported mecha-
nisms for PTEN inactivation are mutations, homozygous dele-
tions, promoter hypermethylation and loss of heterozygosity 
(LOH).13 The most frequent mechanism of reduction or loss of 
PTEN expression in sporadic breast carcinoma is loss of hetero-
zygosity,14 particularly in late stages of disease.15 The aim of this 
study was to investigate the impact of PTEN tumor suppressor 
gene on breast cancer progression and, specifically, to evaluate 
its role in acquiring resistance to tamoxifen, by analyzing loss of 
heterozygosity and immunohystochemical expression of PTEN 
in primary breast carcinomas of patients treated with tamoxi-
fen as the only adjuvant therapy. To that end, we analyzed the 
association of PTEN expression with the recurrence of the dis-
ease, survival rate, stage, grade, tumor size and tumor expression 
of estrogen receptor-α (ER-α), progesterone receptor (PR) and 
Her-2/neu expression.
Results
Clinical and pathological findings. The patients consisted of 49 
postmenopausal steroid receptor positive women who underwent 
modified radical mastectomy. Thirty-nine of them were treated 
by radiation therapy while all patients received standard adjuvant 
tamoxifen therapy. Patients’ characteristics are summarized in 
Table 1. The mean patient follow-up was 114 mo, ranging from 
Table 1. Clinical and histopathological characteristics of patients
Patient Age pTa Cancer typeb Tumor gradus pNc DFSd BCSS statuse OSf OS statusg
45 69 2 IDC 1 1 81 0 81 0
46 65 1 ILC 1 1 67 0 67 0
47 67 1 IDC 2 1 75 0 75 0
48 65 1 IDC 2 0 101 0 101 0
49 81 1 IDC 2 1 156 0 156 1
aTumor size: T1 ≤ 20 mm; T2 > 20–50 mm; T3 > 50 mm. bType of breast carcinoma: ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma. 
cLymph node status: 0, without metastases; 1, lymph node metastases present (1–3 lymph nodes). dDisease free survival in months. eBreast cancer 
specific survival status—death caused by breast cancer: 0, no; 1, yes. fOverall survivals in months until the completion of study. gOverall survival status: 
0, alive at the time of the completion of study; 1, died.
(continuted)
Table 2. Breast cancer immunophenotype
IDC* (%) ILC# (%) Total (%)
ER
high expression 28 (100) 21 (100) 49 (100)
low expression 0 (0.0) 0 (0.0) 0 (0.0)
PR
high expression 18 (64.3) 21 (100) 39 (79.6)
low expression 10 (35.7) 0 (0.0) 10 (20.4)
ER/PR
eR+/pR+ 18 (64.3) 21 (100) 39 (79.6)
eR+/pR- 10 (35.7) 0 (0.0) 10 (20.4)
HER
high expression 4 (14.3) 2 (9.5) 6 (12.2)
low expression 24 (85.7) 19 (90.5) 43 (87.8)
PTEN
high expression 10 (35.7) 12 (57.1) 22 (44.9)
low expression 18 (64.3) 9 (42.9) 27 (55.1)
Total 28 (100) 21 (100) 49 (100)
*Invasive ductal carcinoma (% of total number of IDC), #invasive lobular 
carcinoma (% of total number of ILC).
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tumor, tumor grade, lymph node status and tumor expression of 
ER, PR and HER2. No correlation was found between any of these 
parameters and inactivation of PTEN expression (summarized in 
Table 3). However, inactivation of PTEN immunoexpression sig-
nificantly correlated with the recurrence of the disease (Table 4).
Loss of heterozygosity (LOH) of PTEN tumor-suppressor. 
LOH of PTEN tumor suppressor gene was evaluated by frag-
ment analysis in order to examine genetic bases of the inactiva-
tion of PTEN immunoexpression (Fig. 2). Fragment analysis was 
performed utilizing five highly polymorphic microsatellite mark-
ers, D10S579, D10S1765, D10S541, AFM086wg9 and D10S215, 
mapping at the chromosomal region of PTEN gene. All microsat-
ellite markers were informative. Forty-six of forty-nine analyzed 
samples were informative for at least one microsatellite marker 
while only three samples were not informative at all, that is did 
not show heterozygosity for any locus. Allelic loss for at least one 
marker was observed in 31 (63.3%) of the 49 cases. Eighteen 
samples showed allelic loss at multiple markers. D10S1765 was 
the most frequently lost marker, with the rate of 58%.
(p = 0.7199, two-tailed Fisher’s exact test) or HER2 positive status 
(p = 0.3794, two-tailed Fisher’s exact test). Imunohistochemistry 
was used to analyze the expression of PTEN tumor-suppressor 
in order to test the hypotheses that PTEN might play a role in 
intrinsic or acquired resistance to tamoxifen. High PTEN immu-
nostaining was revealed for 22 samples. Immunoreactivity was 
present in nuclei and/or cytoplasm of malignant cells (Fig. 1A 
and B, respectively) with obvious heterogenity of immunoexpres-
sion on the same slices of tumor tissue (Fig. 1C). Since cutoff 
values for reduced PTEN expression by using immunohisto-
chemical methods have not been defined so far, the mean value 
of PTEN histo-score (H-score) was used to designate reduced 
expression. As a result, 27 (55.1%) samples exhibited total or 
partial inactivation of PTEN expression. Normal breast tissue 
was used as the internal control. In the absence of normal breast 
tissue, immunoreactivity of fibrocytes, nerves and endothelium 
were used as internal control (Fig. 1D).
PTEN immunoexpression was analyzed in relation to clinico-
pathological parameters including tumor size, histological type of 
Figure 1. Immunocytochemical analysis of pTeN expression in breast cancers. (a) Nuclear pTeN immunoreactivity in invasive lobular breast carcinoma 
(IhCx40). (B) Cytoplasmatic pTeN immunoreactivity in invasive ductal breast carcinoma (IhC ×200). (C) heterogeneity of nuclear pTeN immunoreactiv-
ity in invasive ductal breast carcinoma (IhC ×40). (D) Negative pTeN immunoreactivity in invasive ductal breast carcinoma; nerve and fibrocytes as 
positive controls (IhC ×100).
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(BCSS). The most significant observation of this study was that 
LOH of PTEN tumor suppressor was significantly associated with 
shorter disease free survival (p = 0.038) and shorter breast cancer 
specific survival (p = 0.048) regardless of tumor size, type, tumor 
gradus or lymph node metastasis (Fig. 3). In addition, comparison 
of survival curves of patients with altered and wild type PTEN 
showed that LOH of PTEN gene was also significantly associated 
with poorer overall survival (p = 0.049) (Fig. 3).
Cox regression analysis showed inactivation of PTEN by 
LOH to be an independent important determinant of breast can-
cer prognosis. Namely, patients with the LOH of PTEN tumor 
suppressor gene had poor prognosis for disease free survival 
(p = 0.0348; hazard ratio, HR = 2.32; 95% confidential interval, 
CI = 1.02–5.29), breast cancer specific survival (p = 0.0384; HR 
= 2.89, 95% CI = 0.962–8.69) and overall survival (p = 0.0472; 
HR = 2.32, 95% CI = 0.967–5.59).
Inactivation of PTEN gene by LOH was analyzed in relation 
to clinicopathological parameters: tumor subtype, tumor grade, 
tumor size, lymph node status and tumor expression of ER, PR 
and HER2. No correlation was found between any of these param-
eters and inactivation of PTEN by LOH (Table 3), as was the 
case with PTEN immunoexpression. Following the same pattern, 
inactivation of PTEN by LOH and disease recurrence showed sta-
tistically significant correlation (Table 4). Finally, LOH of PTEN 
significantly correlated with the inactivation of PTEN immu-
noexpression (Table 5). Accordingly, it could be concluded that 
inactivation of PTEN immunoexpression is, in the vast majority 
of cases, the consequence of LOH of PTEN gene.
Association between inactivation of PTEN by LOH and sur-
vival. Kaplan-Meier survival curves were generated to evaluate 
the effect of PTEN inactivation by LOH on disease free survival 
(DFS), overall survival (OS) and breast cancer specific survival 
Table 3. association between LOh of pTeN / reduction of PTEN immunoexpression and histopathological parameters
PTEN LOH Reduced PTEN immunoexpression
Parameter Total NSa NSa (%) P value NSa (%) p value
Total 49 31 (63.3) 27 (55.1)
Tumor subtype
IDC 28 20 (71.4) 0.17109 18 (64.3) 0.1584
ILC 21 11 (52.4) 9 (42.9)
Histological grade IDC+ILC
g1 5 5 (100.0) 0.1392b 2 (40.0) 0.6575b
g2 39 22 (56.4) 1.000c 21 (53.8) 0.5238c
g3 5 4 (80.0) 0.6337d 4 (80.0) 0.3702d
IDC histological grade
g1 4 4 (100.0) 0.2622b 2 (50.0) 1.000b
g2 20 12 (60.0) -c 12 (60.0) 0.4286c
g3 4 4 (100.0) 0.2622d 4 (100.0) 0.2622d
ILC histological grade
g1 1 1 (100.0) 1.000b 0 (0.0) 1.000b
g2 19 10 (52.6) 1.000c 9 (47.4) -c
g3 1 0 (0.0) 1.000d 0 (0.0) 1.000d
Lymph node invasion
positive 46 28 (60.8) 0.5231 24 (52.2) 0.5844
Negative 3 1 (33.3) 1 (33.3)
Tumor size
T1 25 16 (64.0) 1.000b 13 (52.0) 0.7736b
T2 21 13 (61.9) 1.000c 12 (57.1) 1.000c
T3 3 2 (66.7) 1.000d 2 (66.7) 1.000d
ER/PR
eR+/pR+ 39 24 (61.5) 0.7258 20 (51.3) 0.4778
eR+/pR- 10 7 (70.0) 7 (70.0)
HER
positive 6 4 (66.7) 1.000 3 (50.0) 1.000
negative 43 27 (62.8) 24 (55.8)
aNs, number of samples per group; bfirst value compared with second value; cfirst value compared with third value; dsecond value compared with third 
value.
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including the anomalous activation of the PI3K/Akt signal-
ing pathway.9,16 This increase in active Akt can result, among 
other things, from the absence or decreased levels of the PIP3 
phosphatase PTEN.17 The aim of this study was to examine the 
potential role of PTEN tumor suppressor in acquiring resistance 
to tamoxifen in primary breast carcinoma patients. We found 
Discussion
The main reason why treatment with tamoxifen fails in the major-
ity of patients with ER-positive breast cancer is the development 
of drug resistance, either intrinsic or acquired. Multiple factors 
have been implicated in the generation of tamoxifen resistance, 
Figure 2. Representative example of LOh analyses of pTeN tumor suppressor gene with D10s1765 microsatellite marker, showing loss of allele 178 
(arrow) in tumor sample (T) compared to its normal counterpart (N).
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shorter relapse-free survival and shorter disease-specific survival 
in breast cancer patients on tamoxifen treatment. In addition, 
they showed a significant negative association between PTEN 
expression and the presence of lymph node metastasis suggest-
ing that loss of PTEN may also be involved in promotion of the 
invasive properties of the tumor. Similar results were disclosed 
a high frequency (55.1%) of decreased or com-
plete loss of PTEN expression by immunostain-
ing in a series of 49 primary breast carcinomas, 
considerably higher than in previously reported 
studies.12,18 We further investigated LOH as the 
major mechanism responsible for the decreased 
PTEN expression in sporadic breast carcinoma14 
using fragment analyses. Fragment analyses 
revealed 63.3% of samples having lost at least one 
of five examined markers defining PTEN, which 
is within the frequency range of samples with 
reduced PTEN immunoexpression. Importantly, 
inactivation of PTEN immunoexpression signifi-
cantly correlated with the PTEN loss of hetero-
zygosity, confirming LOH as the most important 
genetic mechanism for the inactivation of PTEN 
in primary breast carcinoma.
Observed frequency of PTEN LOH is signifi-
cantly higher than previously reported14,15,19 and 
the explanation of this discrepancy may lie in the 
evolution of tumor under selective pressure pro-
vided by tamoxifen treatment. Namely, correla-
tion analysis displayed a significant association 
between inactivation of PTEN immunoexpres-
sion by LOH and recurrence of the disease which 
suggests poor response to tamoxifen treatment. 
Accepting the fact that genomic instability is 
the hallmark of cancer that drives cancerogen-
esis under unfavorable conditions20,21 such as the 
presence of tamoxifen, genotypes with favorable 
effects on cell growth are likely to be promoted. 
In other words, we think that the loss of hetero-
zygosity of PTEN tumor suppressor gene is an 
important genetic event leading to a reduction 
or complete loss of PTEN protein expression, 
the consequence of which is anomalous activa-
tion of the PI3K/Akt survival pathway followed 
by acquiring resistance to tamoxifen and recur-
rence of the disease. Our supposition is limited 
by the fact that we have not examined the PI3K/
Akt signaling pathway but in the light of infor-
mation from cell culture studies,17,22 it may be 
proposed that reduced PTEN expression can 
result in increased activity of PI3K/Akt survival 
pathway, which interferes with cellular actions 
of tamoxifen thus resulting in tumor recurrence. 
Our results obtained from the follow-up stud-
ies are supportive of above thesis. Kaplan-Meier 
survival curves revealed that LOH of PTEN 
tumor suppressor was significantly associated 
with shorter disease free survival, shorter breast cancer specific 
survival and shorter overall survival. These findings were inde-
pendent of tumor subtype, tumor grade, tumor size, lymph node 
status and tumor expression of ER, PR and HER2. In agreement 
with our findings are those of Shoman et al.12 who obtained 
significant association between reduced PTEN expression and 
Figure 3. Kaplan-Meier survival curves. patients with reduced or lost immunoexpres-
sion of pTeN due to loss of heterozygosity showed significantly shorter (a) disease-free 
survival, (B) breast cancer-specific survival and (C) overall survival.
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Signed informed consent was obtained from each of the 
patient. The written consent was acquired according to the ethi-
cal standards laid down in the 1964 Declaration of Helsinki, 
the International Ethical Guidelines for Biomedical Research 
Involving Human Subjects (CIOMS), Geneva 1993 and the 
Guidelines for Good Clinical Practice (CPMP/ICH/135/95), 
September 1997.
Immunohistochemistry. We performed a manual immuno-
hystochemical technique with primary monoclonal mouse anti-
human PTEN clone (1:100, Clone 6H2.1, Dako) with EnVision+ 
system (HRP Labeled Polymer, K4000, Dako) and chromogen 
Dako Dab liquid (K3468). Labeled streptavidin-biotin-LSAB+ 
method together with immunoperoxidase was used according 
to recommended procedure for commercial primary monoclo-
nal mouse antibody: anti-human ERα clone (1:50; Clone 1D5; 
Dako) and anti-human PR clone (1:50; Clone PgR 636; Dako), 
as well as for policlonal rabbit antibody anti-human c-erbB2/
HER2 oncoprotein (1:300; Dako) with Dako LSAB+/HRP kit 
(K0679). Slices were contrasted with Mayer hematoxylin.
We assessed the immunoreactivity of PTEN using the semi-
quantitative method based on the score of percentage of stained 
cells-cytoplasm/nuclei (0, no immunoreactivity; 1, 1–10%; 2, 
11–50%; 3, 51–100%) and intensity of staining (0, no immu-
noreactivity; 1, reduced staining intensity relative to the cor-
responding normal cells; 2, same as normal cells staining; 3, 
mildly increased staining; 4, moderately increased staining; 5, 
intensely increased staining). Immunoreactivity of normal sur-
rounding breast tissue (duct epithelium, myoepithelial cells, 
endothelium, fibrocytes and nerves was used for the internal 
positive control).24 Since cutoff levels for reduced PTEN expres-
sion by using immunohistochemical methods have not been 
defined so far, we used the mean PTEN score as a cutoff point to 
designate reduced expression.12 Accordingly, PTEN status was 
defined as follows: low expression if score was ≤ 5; high expres-
sion if score was > 5.
The evaluation of steroid receptors (ER, PR) was based on 
the scoring system which included percentage of stained malig-
nant nuclei (0–5) and their intensity of staining (0–3); positive 
(high expression) cases were with score ≥ 4 while negative (low 
expression) cases were with score < 4.25 HER2 status was deter-
mined using DAKO scoring system and HER2 positive status 
was defined if IHC score was 2+/3+.26
DNA Extraction and LOH Analysis. DNA was isolated from 
formalin-fixed/paraffin-embedded tissue of 49 pared, tumor and 
corresponding normal, samples. Tissue sections were cut into 
5 μm-thick slices and DNA extracted according to the protocol 
by Depowski et al.18 who showed negative association between 
PTEN expression and the presence of lymph node metastasis 
and Garcia et al.19 who found statistically significant difference 
between PTEN LOH and lymph node metastases, as well as 
between PTEN LOH and tumor gradus. Contrary to these 
findings, our results did not reveal correlation between any of 
the examined clinicopathological parameters and reduction of 
PTEN expression or PTEN LOH. Based on these results we 
cannot argue whether loss of PTEN expression is an early or a 
late event in breast carcinogenesis. Some reports suggest that it 
is a late event associated with tumor progression and not tumor 
initiation, at least in the breast cancer model.
In conclusion, our findings suggest that PTEN loss of hetero-
zygosity is the major mechanism responsible for the loss or reduc-
tion of PTEN expression which may interfere with the effects of 
tamoxifen leading to tamoxifen resistance and disease recurrence 
with poor outcome. Moreover, as revealed by Kaplan-Meier test 
and Cox regression analysis, PTEN LOH showed to be a good 
prognostic characteristic for the disease outcome of breast cancer 
patients treated with tamoxifen.
Materials and Methods
Patients. This is a retrospective study comprised of 49 ER and/
or PR positive primary breast cancer and 49 corresponding nor-
mal tissue samples obtained from postmenopausal women. All 
patients underwent modified radical mastectomy between 1988 
and 1995 at the Institute of Oncology and Radiology of Serbia. 
As per protocol at that time, all of them received adjuvant endo-
crine therapy tamoxifen for 5 years (without adjuvant chemo-
therapy) and 39 of 49 patients were postoperatively irradiated. 
All relevant clinical parameters [age, tumor size, lymphonodal 
status, disease free survival (DFS), overall survival (OS), breast 
cancer specific survival (BCSS)] were retrieved from patients 
medical records.
Collected tumor specimens and corresponding normal tissue 
were formalin-fixed, paraffin-embedded and hematoxylin-eosin 
(HE) stained. Histological type and grade of each carcinoma 
sample were determined after hematoxylin-eosin staining. The 
carcinomas were graded (I–III) according to Scarff-Bloom-
Richardson scoring system.23 All histopathological parameters 
were reviewed by two independent pathologists blinded to clini-
cal outcome, results obtained by other pathologist and results of 
LOH analysis. Axillary lymph node status was determined as 
score 0 for absence of metastases and score 1 for 1–3 metastatic 
lymph nodes.
Table 4. association between inactivation of pTeN and recurrence of disease
PTEN inactivation Loss of Heterozygosity PTEN inactivation Immunophenotype
LOH+ LOH- PTEN+ PTEN-
Variables Npa (%) Np (%) p value Np (%) Np (%) p value
Recurrence
Yes 18 (36.7) 4 (8.2) 4 (8.2) 26 (53.1)
No 13 (26.5) 14 (28.6) 0.0193* 18 (36.7) 1 (2.0) 0.000**
aNp, number of samples per group; *indicates statistically significant values, p ≤ 0.05; **indicates statistically significant values, p ≤ 0.001.
©
20
12
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
www.landesbioscience.com Cancer Biology & Therapy 1173
described by Shi et al.27 Tumor DNA was isolated only from 
slices that contained 70% or more of tumor cells.
Loss of heterozygosity of PTEN tumor suppressor was deter-
mined by fragment analysis using a set of five highly polymor-
phic microsatellite markers that map at the 10q23 chromosome 
region: D10S579, D10S215, D10S1765, AFMa086wg9 and 
D10S541. All markers were CA-dinucleotide repeats and are pre-
sented in a centromere-to-telomere orientation. Forward primers 
for all markers were 5'-labeled with Fam fluorescent dye, except 
for AFMa086wg9 which was PET labeled (Applied Biosystems). 
Markers were chosen from published sources following the cri-
teria of heterozygosity (heterozygosity value greater than 0.7) in 
miscellaneous human populations and the position of marker 
(markers had to span the whole PTEN loci). Locus-specific PCR 
reagents and conditions were as described previously.28,29
Locus specific, florescent dye-labeled PCR products were pre-
pared according to the manufacturer’s instructions. Amplicons 
were mixed with HiDi formammide and GeneScan-500 LIZ 
Size Standard, denaturated at 95°C for 5 min, cooled on ice 
for 10 min and, finally, separated by capillary array electropho-
resis (filed with polymer type 7, POP-7, Applied Biosystems) 
on an ABI Prizm 3130 automated Genetic Analyzer (Applied 
Biosystems). Row data were collected and subsequently analyzed 
using GeneMapper Software. DNA from normal breast tissue of 
the same patient was used as a reference. A marker was defined as 
informative when two allelic peaks were identified in florescent 
histogram of reference DNA (it was heterozygous). When only 
one allelic peak was noted in control DNA, a marker was con-
sidered non-informative (it was homozygous) and therefore not 
useful for LOH scoring. The same way of reasoning was applied 
for separate samples—a sample was considered informative when 
it was heterozygous for at least one locus and non-informative 
when it was homozygous for all five loci. LOH candidates were 
determined after calculating allelic imbalance (AI) between nor-
mal and tumor tissues. For all informative cases, allelic imbal-
ance was determined by comparing the calculated peak height 
ratios of microsatellite alleles between normal and tumor tissue 
of the same patient according to the following formula: (peak 
high of normal allele 2)/(peak high of normal allele 1) divided 
by (peak high of tumor allele 2)/(peak high of tumor allele 1). A 
sample was flagged as LOH candidate for particular marker if the 
value of allelic imbalance (AI) was above 1.35 or below 0.67 (AI 
> 1.35 or AI < 0.67).
Table 5. association between LOh and immunoexpression of pTeN 
gene
PTEN reduced immunoexpression
Yes No
Variables Npa (%) Np (%) p value
PTEN LOH
Yes 21 10 0.0359*
No 6 12
aNp, number of samples per group; *indicates statistically significant 
values, p ≤ 0.05.
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